Sleep deprivation and antidepressant treatment

The mood-improving effect of sleep deprivation (SD) in depression is even today still not fully understood. Despite the fact that mood and cognitive functions are lowered by prolonged sleep loss and despite convincing data that insomnia is a strong risk factor for subsequent depression, acute SD for one night or even partial SD in the second half of the night improves mood in about 60% of depressed patients the day after. In this respect, among all types of antidepressant treatments, SD elicits the fastest results, faster even than electroconvulsive therapy. Many authors correlate the likelihood of responding to SD with clinical variables. A summary of predictors is listed in Table I.

The main limitation is the transient nature of the effect, since the majority—but not all—of the improved patients experience a relapse after the next night of sleep. Despite the rapid effects and low risk of relevant side effects (Table I), the method has remained an “orphan drug” or “orphan method.” This may be explained not only by the effort and motivation needed by the patient and by the frequent relapses after the next night of sleep, but also by the lack of funding for nonpharmacological and nonneurochemical research. Nevertheless, some progress has been made within the last few years. A variety of studies have focused on the problem of how to avoid relapses occurring after the next night of sleep and additionally treated the patients with light therapy, lithium, or other drugs. Lower relapse rates after SD were found when SD was combined with one of these therapeutic options (Table II). A further strategy has been to advance the sleep period to an “unphysiological” time. Several uncontrolled studies in small numbers of patients have indicated that this phase advance procedure per se acts as an antidepressant. More recent studies have combined SD with a subsequent phase advance of the sleep period, over the course of either six or three nights and consistently found that a phase advance of the sleep period stabilizes the antidepressant effect of SD in about 60% of those patients who responded positively to SD. Only one study also included a control group which participated in a phase-delay protocol after SD instead of a phase-advance protocol. Significantly more patients relapsed in the phase-delay protocol compared with the phase advance protocol (Figure 1). This indicates that the high...
response rate after SD and phase advance cannot be explained by a placebo phenomenon alone and supports the hypothesis that, in depressed subjects, sleeping at certain phases of the circadian rhythm, ie, especially late in the night and in the morning, has depressogenic effects. Unfortunately, one major issue has been almost completely neglected by researchers: does SD produce any lasting effects after 4 to 6 weeks, which is the typical period for measuring the effects of antidepressants? There is only one controlled study using such a design. Twenty-four patients received amitriptyline without additional SD, whereas 27 patients received amitriptyline plus a series of 6 partial SDs. Observer ratings, but not patient ratings, demonstrated superiority of the combined treatment after 4 weeks. By the standards of evidence-based medicine, there is little evidence to date that SD therapy has lasting effects over the course of several weeks.

**Neurobiology of SD in depression**

There is no generally accepted hypothesis concerning the mechanism of action of SD, nor an explanation for the observation that subsequent sleep after SD leads to relapses. A variety of neurobiological effects point toward potential mechanisms of action of the procedure (Table III). Based on the observations that hyperarousal and a high level of activation predict a favorable SD response, the antidepressant effect was explained using the two-process model of sleep regulation (Figure 2). In this model, depressed patients have a deficiency of process S (ie, sleep need) with process C (circadian rhythm) remaining unaffected. Depression is characterized by a deficient build-up of process S (Figure 2). SD transiently leads to an increase in process S to normal, whereas relapse occurs after “recovery sleep” due to a return to low levels of S.

Several brain imaging studies have tried to correlate the SD response with metabolic states of certain brain areas. Two early studies using single photon emission computed tomography (SPECT) and positron emission tomography (PET), respectively, found higher metabolic rates in limbic areas in responders compared with nonresponders. A more recent study confirmed these earlier findings: responders to SD had higher relative metabolic rates in the ventral anterior cingulate and in the medial prefrontal cortex (Figure 3), as well as in the posterior subcallosal gyrus at baseline than depressed patients who did not respond to SD and normal volunteers. After SD, significant decreases in metabolic rates occurred in the medial prefrontal cortex and frontal pole in the patients who responded positively to SD. The brain imaging studies convincingly demonstrated that acute antidepressant SD is able to change metabolic states of brain areas that are involved in mood regulation. Many studies have assessed endocrine parameters before and after SD. The results have been inconsistent, which may be partially explained by methodological shortcomings. Several authors favor the hypothesis that the hypothalamo-pituitary-thyroid (HPT) axis plays a key role in mediating the antidepressant effects of SD.

---

**Table III.** Neurobiological effects of sleep deprivation. In humans some of the studies were performed in depressed patients, while other studies were in healthy subjects or in depressed patients and healthy subjects.

- Decrease in limbic hypermetabolism
- Increase in dopamine turnover
- Increase in peripheral cytokines
- Increase in cortisol
- Increase in growth hormone secretion (recovery sleep)
- Increase in thyroid hormones

---

**Figure 1.** Antidepressant effects of total sleep deprivation (TSD) in one night with a consecutive phase advance of the sleep period (blue circles) in comparison with a phase delay of the sleep period (gray circles). In the phase-advance group, the antidepressant effect of SD (between day 0 and day 1) was stabilized until day 8, whereas in the phase-delay group mood worsened again (mood was measured by a short version of the Hamilton Depression Rating Scale [HDRS], containing 6 items). This scale is suitable for frequent ratings, whereas the 21-item HDRS would not have been adequate within the study design.

---

**Poster by:** Ulrich Voderholzer, MD, PhD
Department of Psychiatry and Psychotherapy, Klinikum of the Albert-Ludwig-University, Hauptstrasse 5, 79104 Freiburg, Germany
(Ulrich_Voderholzer@psyallg.ukl.uni-freiburg.de)

www.dialogues-cns.org
Another issue is the impact of SD on the hypothalamic-adrenal (HPA) axis. Increased activity of this axis is one of the most consistent abnormalities in depression and normalization of this hyperactivity is a correlate of clinical remission and has been suggested as the mechanism of action of antidepressant treatment. In healthy humans, acute SD increases cortisol secretion. In a study that we conducted ourselves, we found a significant stimulatory effect of acute SD on nighttime cortisol in a group of unmedicated depressed subjects, which was not related to treatment response. However, during the first day of SD, there is a decrease in cortisol secretion, which returns to normal after the first night of recovery sleep. This suggests that the antidepressant effect of SD is not related to the initial increase in cortisol secretion, but rather to the subsequent decrease.

Figure 2. Two-process model of sleep deprivation (SD) and depression. This model can explain the antidepressant effect of SD by assuming that an insufficient build-up of process T (S stands for sleep need) and SD transiently increases the level of process T, thus, leading to the antidepressant effect. Recovery sleep decreases process T to baseline levels leading to relapse into the depressed state. This model fits well with clinical observations that depressed patients have hyperarousal, which has been shown to be a positive predictor of the SD response.

Reproduced from reference 33: Borbély AA, Wirz-Justice A. Sleep, sleep deprivation and depression. Hum Neurobiol. 1982;1:205-210. Copyright © 1982, Springer-Verlag.

REFERENCES

1. Riemann D, Voderholzer U. Primary insomnia: a risk factor to develop depression? J Affect Disord. 2003;76:247-251.
2. Wu JC, Bunney WE. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry. 1990;147:14-21.
3. Van den Hoofdakker RH. Total sleep deprivation: clinical and theoretical aspects. In: Honig A, van Praag HM, eds. Depression: Neurobiological, Psychopathological and Therapeutic Advances. Chichester, UK: John Wiley & Sons Ltd; 1997:563-589.
4. Bouhuys AL, van den Burg W, van den Hoofdakker RH. The relationship between tiredness prior to sleep deprivation and the antidepressant response to sleep deprivation in depression. Biol Psychiatry. 1995;37:457-461.
5. Gordijn MC, Beersma DG, Bouhuys AL, Reinink E, Van den Hoofdakker RH. A longitudinal study of diurnal mood variation in depression: characteristics and significance. J Affect Disord. 1994;31:261-273.
6. Reinink E, Bouhuys N, Wirtz-Justice A, van den Hoofdakker R. Prediction of the antidepressant response to total sleep deprivation by diurnal variation of mood. Psychiatry Res. 1990;32:113-124.
7. Barbini B, Colombo C, Benedetti F, Campori E, Bellodi L, Smeraldi E. The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res. 1998;74:43-50.
8. Colombo C, Benedetti F, Barbini B, Campori E, Smeraldi E. Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression. Psychiatry Res. 1999;86:267-270.
9. Benedetti F, Zanardi R, Colombo C, Smeraldi E. Worsening of delusional depression after sleep deprivation: case reports. J Psychiatr Res. 1999;33:69-72.
10. Elenga S, van den Hoofdakker RH. Clinical effects of sleep deprivation and clomipramine in endogenous depression. J Psychiatr Res. 1982;17:361-74.
11. Baxter LR Jr, Liston EH, Schwartz JM, et al. Prolongation of the antidepressant response to partial sleep deprivation by lithium. Psychiatry Res. 1986;19:17-23.
12. Grube M, Hartwich P. Maintenance of antidepressant effect of sleep deprivation with the help of lithium. Eur Arch Psychiat Neurol Sci. 1990;240:60-61.
13. Szuba MP, Baxter LR Jr, Althuler LL, et al. Lithium sustains the acute antidepressant effects of sleep deprivation: preliminary findings from a controlled study. Psychiatry Res. 1994;51:283-295.
14. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology. 1999;20:380-385.
15. Neumeister A, Goessler R, Lucht M, Kapitany T, Bamas C, Kasper S. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biol Psychiatry. 1996;39:16-21.
16. Colombo C, Luca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Res. 2000;95:43-53.
17. Berger M, Vollmann J, Hohagen F, et al. Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. Am J Psychiatry. 1997;154:870-872.
18. Riemann D, König A, Hohagen F, et al. How to preserve the antidepressant effect of sleep deprivation: a comparison of sleep phase advance and sleep phase delay. Eur Arch Psychiatry Clin Neurosci. 1999;249:231-237.
19. Benedetti F, Barbini B, Campori E, Fulgosi MC, Pontigia G, Colombo C. Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: new findings supporting the internal coincidence model? J Psychiatr Res. 2001;35:323-329.
20. Voderholzer U, Valierius G, Schaefer L, et al. Is the antidepressive effect of sleep deprivation stabilized by a three day phase advance of the sleep period? A pilot study. Eur Arch Psychiatry Clin Neurosci. 2003;253:68-72.
21. Huw H, Färber D, Borgstädte S, Mrosek S, Tölle R. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. J Affect Disord. 1996;37:31-41.
22. Ebert D, Feistel H, Barocka A. Effects of sleep deprivation on the limbic system and the frontal lobes in affective disorders: a study with Tc-99m-HMPAO SPECT. Psychiatry Res. 1991;40:247-251.
23. Wu JC, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE Jr. Effect of sleep deprivation on brain metabolism of depressed patients. Am J Psychiatry. 1992;149:538-543.
In summary, the SD response in depressive patients remains a highly interesting issue for depression research, since, contrary to all antidepressant drugs, it may significantly ameliorate mood within one day. Understanding this effect and optimizing the duration of the effect, ie, preventing relapse after the response, might improve our ability to treat depression.

24. Wu J, Buchsbaum MS, Gillin JC, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. Am J Psychiatry. 1999;156:1149-1158.

25. Ebert D, Berger M. Neurobiological similarities in antidepressant sleep deprivation and psychostimulant use: a psychostimulant theory of antidepressant sleep deprivation. Psychopharmacology. 1998;140:1-10.

26. Dingess DF, Douglas SD, Hamarman S, Zaugg L, Kapoor S. Sleep deprivation and human immune function. Adv Neuromunol. 1995;5:97-110.

27. Voderholzer U, Hohagen F, Herr A, et al. Effects of sleep deprivation on cytokines in healthy and depressed subjects. In: Spener-Unterweger B, Fleischhacker WW, Kaschka WP, eds. Psychoneuroimmunology. Hypotheses and Current Research. Advances in Biological Psychiatry. Basel, Switzerland: Karger; 2001;20:98-109.

28. Leprout R, Copinschi G, Buxton O, Van-Cauter E. Sleep loss results in an elevation of cortisol levels the next evening. Sleep. 1997;20:865-870.

29. Spiegel K, Leprout R, Van-Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999;354:1435-1439.

30. Voderholzer U, Weske G, Klein T, et al. Endocrine studies during sleep, sleep deprivation, and recovery sleep in depressed patients. Neuropsychopharmacology. 2000;23(suppl 2):S82-S83.

31. Parekh PI, Ketter TA, Altshuler L, et al. Relationships between thyroid hormone and antidepressant responses to total sleep deprivation in mood disorder patients. Biol Psychiatry. 1998;43:392-394.

32. Orth DN, Shelton RC, Nicholson WE, et al. Serum thyrotropin concentrations and bioactivity during sleep deprivation in depression. Arch Gen Psychiatry. 2001;58:77-83.

33. Borbély AA, Wirz-Justice A. Sleep, sleep deprivation and depression. Hum Neurobiol. 1982;1:205-210.

34. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev. 1996;17:187-205.

35. Goodwin GM, Muir WJ, Selkirk JR, et al. The effects of cortisol infusion upon hormone secretion from the anterior pituitary and subjective mood in depressive illness and in controls. J Affect Disord. 1992;26:73-83.

36. DeBattista C, Posener JA, Kalish BN, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2000;157:1334-1337.

37. Volkow ND, Wang GJ, Fowler JS, et al. Gender differences in cerebellar metabolism: text-retest reproducibility. Am J Psychiatry. 1997;154:50-55.

38. Marinelli M, Rouge-Pont F, Deroche V, et al. Glucocorticoids and behavioral effects of psychostimulants. I: Locomotor response to cocaine depends on basal levels of glucocorticoids. J Pharmacol Exp Ther. 1997;281:1392-1400.